院内心脏骤停患者心肺复苏期间平均动脉压与预后的关系
该研究纳入2020年1月至2022年12月徐州医科大学附属医院急诊科收治的486例院内心脏骤停患者,按复苏期间时间加权平均动脉压(TWA-MAP)分为低水平组(<65 mmHg,350例)、中水平组(65–85 mmHg,63例)和高水平组(≥85 mmHg,73例)。中、高水平组的自主循环恢复率、3天生存率和神经功能良好结局率均高于低水平组(自主循环恢复率:82.5%、75.3% vs. 17.1%;3天生存率:36.5%、23.3% vs. 5.1%;神经功能良好结局率:12.7%、12.3% vs. 1.7%;均P<0.05),中、高水平组间无显著差异(均P>0.05)。多因素分析显示65 mmHg≤TWA-MAP<85 mmHg是3天生存的保护因素(OR=3.040,95%CI 1.436–6.437,P=0.004)和自主循环恢复的保护因素(OR=4.421,95%CI 1.013–19.280,P=0.048),TWA-MAP≥85 mmHg被识别为3天内死亡的风险因素(OR=0.390,95%CI 0.153–0.994,P=0.049)。TWA-MAP对自主循环恢复有较高预测价值(AUC=0.886,95%CI 0.852–0.919),切点60 mmHg时敏感度90.7%、特异度66.2%。
要点
- 复苏期间TWA-MAP 65–85 mmHg组3天生存率36.5%,高于<65 mmHg组的5.1%(P<0.05)。
- TWA-MAP≥85 mmHg组3天生存率23.3%,仍高于<65 mmHg组的5.1%(P<0.05)。
- TWA-MAP 65–85 mmHg是自主循环恢复的保护因素(OR=4.421,95%CI 1.013–19.280,P=0.048)。
- TWA-MAP预测自主循环恢复的AUC为0.886(95%CI 0.852–0.919),切点60 mmHg时敏感度90.7%、特异度66.2%。
- TWA-MAP≥85 mmHg与65–85 mmHg两组间自主循环恢复率、3天生存率、神经功能良好结局率均无显著差异(均P>0.05)。
适用人群与场景
- 2020年1月至2022年12月徐州医科大学附属医院急诊科收治的院内心脏骤停患者,共486例。
诊断标准与关键阈值
- 按复苏期间时间加权平均动脉压(TWA-MAP)分组:低水平组TWA-MAP<65 mmHg(1 mmHg=0.133 kPa),中水平组65 mmHg≤TWA-MAP<85 mmHg,高水平组TWA-MAP≥85 mmHg。
研究设计与关键结果
- 回顾性纳入486例院内心脏骤停患者,低水平组350例、中水平组63例、高水平组73例,三组性别、年龄、病史及心脏骤停特征等指标无显著差异。
- 中水平组和高水平组自主循环恢复率分别为82.5%、75.3%,均高于低水平组的17.1%(P<0.05);中、高水平组间无显著差异(P>0.05)。
- 中水平组和高水平组3天生存率分别为36.5%、23.3%,均高于低水平组的5.1%(P<0.05);中、高水平组间无显著差异(P>0.05)。
- 中水平组和高水平组神经功能良好结局率分别为12.7%、12.3%,均高于低水平组的1.7%(P<0.05);中、高水平组间无显著差异(P>0.05)。
- 多因素二元Logistic回归:65 mmHg≤TWA-MAP<85 mmHg是3天生存的保护因素(OR=3.040,95%CI 1.436–6.437,P=0.004);TWA-MAP≥85 mmHg被识别为3天内死亡的风险因素(OR=0.390,95%CI 0.153–0.994,P=0.049);65 mmHg≤TWA-MAP<85 mmHg是自主循环恢复的保护因素(OR=4.421,95%CI 1.013–19.280,P=0.048);两范围均不是神经功能良好结局的独立预测因素(均P>0.05)。
- 暴露-反应曲线显示自主循环恢复率和3天生存率随TWA-MAP升高而增加;TWA-MAP达60 mmHg时自主循环恢复率超过60%,达80 mmHg时自主循环恢复率约80%并进入平台期;3天生存率在TWA-MAP 60 mmHg时为20.3%,76 mmHg时达峰值37.2%,之后下降;神经功能良好结局率随TWA-MAP升高呈上升趋势但无统计学显著性。
- ROC曲线分析:TWA-MAP预测自主循环恢复的AUC=0.886(95%CI 0.852–0.919),切点60 mmHg时敏感度90.7%、特异度66.2%;预测3天生存的AUC=0.843(95%CI 0.777–0.909),切点60 mmHg时敏感度73.5%、特异度79.8%。
证据类型、等级与局限
- 证据类型:回顾性队列研究(基于急诊病历系统纳入徐州医科大学附属医院急诊科2020年1月至2022年12月院内心脏骤停患者)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为院内心脏骤停患者复苏期间维持较高水平平均动脉压与更好的生存率相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the association and predictive value of mean arterial pressure (MAP) during cardiopulmonary resuscitation (CPR) regarding prognosis in patients with in-hospital cardiac arrest (IHCA).
METHODS: IHCA patients admitted to the emergency department of the Affiliated Hospital of Xuzhou Medical University from January 2020 to December 2022 were enrolled via the emergency medical record system. Based on the time-weighted average mean arterial pressure (TWA-MAP) levels during CPR, patients were divided into a low-level group (TWA-MAP<65 mmHg, 1 mmHg=0.133 kPa), a mid-level group (65 mmHg≤TWA-MAP<85 mmHg), and a high-level group (TWA-MAP≥85 mmHg). The rates of return of spontaneous circulation (ROSC), 3-day survival, and favorable neurological outcome were compared among the three groups. Multivariable binary Logistic regression analysis was used to explore factors influencing ROSC success rate, 3-day survival rate and favorable neurological outcome rate. Generalized additive model (GAM) was employed to analyze and construct exposure-response curves for TWA-MAP in relation to ROSC success rate, 3-day survival rate and favorable neurological outcome rate, respectively. Receiver operator characteristic curve (ROC curve) analysis was applied to evaluate the predictive value.
RESULTS: A total of 486 patients were included, with 350 in the low-level group, 63 in the medium-level group, and 73 in the high-level group. There were no significant differences in indicators such as gender, age, medical history, and characteristics of cardiac arrest among the three groups. The ROSC success rate, 3-day survival rate, and favorable neurological outcome rate in the medium and high-level groups were higher than those in the low-level group (ROSC success rate: 82.5%, 75.3% vs. 17.1%; 3-day survival rate: 36.5%, 23.3% vs. 5.1%; favorable neurological outcome rate: 12.7%, 12.3% vs. 1.7%; all P<0.05). There were no significant differences observed between the medium and high-level groups (all P>0.05). Multivariable binary Logistic regression showed that 65 mmHg≤TWA-MAP<85 mmHg during CPR was a protective factor for 3-day survival [odds ratio (OR)=3.040, 95% confidence interval (95%CI) was 1.436-6.437, P=0.004], TWA-MAP≥85 mmHg was identified as a risk factor for mortality within 3 days (OR=0.390, 95%CI was 0.153-0.994, P=0.049). 65 mmHg≤TWA-MAP<85 mmHg served as a protective factor for achieving ROSC (OR=4.421, 95%CI was 1.013-19.280, P=0.048). Neither 65 mmHg≤TWA-MAP<85 mmHg nor TWA-MAP≥85 mmHg were independent predictors of favorable neurological outcome in patients (both P>0.05). Exposure-response curve indicated that ROSC success rate and 3-day survival rate increased with higher TWA-MAP. When TWA-MAP reached 60 mmHg, the ROSC success rate exceeded 60%; when at 80 mmHg, the ROSC success rate reached a plateau of approximately 80%. For 3-day survival, the rate reached 20.3% at a TWA-MAP of 60 mmHg, peaked at 37.2% at 76 mmHg, and declined thereafter. Although the favorable neurological outcome rate trended upward with increasing TWA-MAP, the correlation was not statistically significant. ROC curve analysis demonstrated that TWA-MAP had high predictive value for ROSC [area under the curve (AUC)=0.886, 95%CI was 0.852-0.919]; at a TWA-MAP cut-off of 60 mmHg, sensitivity was 90.7% and specificity was 66.2%. TWA-MAP also had predictive value for 3-day survival, with an AUC of 0.843 (95%CI was 0.777-0.909); at a TWA-MAP cut-off of 60 mmHg, sensitivity was 73.5% and specificity was 79.8%.
CONCLUSIONS: Maintaining a higher level of MAP during CPR is associated with better survival rate in IHCA patients.
参考来源
- Ding Q, Wang J, Su C, et al. [Relationship between prognosis and mean arterial pressure of in-hospital cardiac arrest patients during cardiopulmonary resuscitation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42281540. doi:10.3760/cma.j.cn121430-20251106-00542
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。